InnovAge Puts DOJ False Claims Act Case Behind It With Civil Settlement
INNV sits 90% above its 52-week low of $4.7.
Summary
InnovAge resolved its civil False Claims Act matter with the U.S. Department of Justice and participating states, closing out the overhang that has hung over the stock. The company had already booked roughly $36.9M for the DOJ/state settlement in the fiscal 2027 first quarter, so the cash hit is largely known; what's new is formal closure of the case. Removing the litigation cloud matters for a company that just posted 12.1% revenue growth to $264.8M and net income of $20.9M in fiscal Q1. The 10-K also flagged a $37M litigation accrual, so the balance-sheet impact is already reflected. Watch the December 3, 2026 annual meeting, the company's first say-on-pay vote.
At the time of this announcement, INNV was trading at $8.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $4.70 to $12.64. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.